Special Issue "Oxidative Stress– and Redox–Based Therapeutic Strategy in Cancers"
Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 6821
Reactive oxygen species (ROS) homeostasis and dynamic intracellular reductive/oxidative (redox) balance play a key role in cell physiology and contribute to cell fate decisions. In many cancer cells, cellular events such as activation of oncogenes, aberrant metabolic stress, and mitochondrial dysfunction can increase ROS levels, leading to intrinsic oxidative stress and a persistent pro-oxidative status. Therefore, the malignant cells are more dependent on antioxidants for cell survival and more vulnerable to further oxidative insults than their normal counterparts. It is conceivable that we could induce preferential cancer cell death by pharmacological interventions targeting the cellular redox system. This is the biological basis of oxidative stress- and redox-based anticancer strategy that could have significant therapeutic implications. Furthermore, it has been demonstrated that, at least in some cases, redox adaptation plays an important role in intrinsic or acquired resistance to chemotherapy/radiotherapy. Redox modulation to abrogate such adaptation mechanisms in combination with conventional chemotherapy or radiotherapy can also be exploited for therapeutic benefits.
This Special Issue is devoted to publishing original research articles on redox alterations and redox adaptation mechanisms in cancer cells and cancer stem cells, mechanisms of action of redox-modulating agents and drug combinations, and translational studies and clinical evaluations. Review articles on these topics are also welcome. We aim to provide a comprehensive update on oxidative stress- and redox-based therapeutic strategies in cancers.
Dr. Meng-Er Huang
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- reactive oxygen species
- oxidative stress
- redox modulation
- redox adaptation
- cancer cells
- cancer stem cells
- drug combinations
- anticancer strategies